There is a growing swell of concern about the use of antibiotics in the poultry and meat industry. The January 2013 International Production & Processing Expo included an Antibiotic Conference that focused on “Current Issues for the Poultry & Egg Industry.” A February release from the U.S. Poultry & Egg Association stated that the U.S. Food and Drug Administration (FDA) is moving forward with its plan to limit use of medically important antimicrobial drugs to those considered necessary for assuring animal health. Regulatory changes are partly responsible for the growing interest in alternatives to intensive antibiotic use in the poultry industry.
In June 2012, Consumer Reports reported that “approximately 80 percent of all antibiotics (approximately 29 million pounds) sold in the U.S. are used by the meat and poultry industry to make animals grow faster or to prevent disease in crowded and unsanitary conditions.”
PBS reports that “concern about the growing level of drug-resistant bacteria has led to the banning of sub-therapeutic use of antibiotics in meat animals in many countries in the European Union and Canada. In the U.S., such use is still legal. The World Health Organization is concerned enough about antibiotic resistance to declare their intention of reducing “the overuse and misuse of antimicrobials in food animals for the protection of human health."Salmogenics improves the immune system, resulting in a healthier chicken. This “green” vaccine contains natural organisms that are not genetically modified. It stimulates an immune response in chickens produced from inoculated eggs to several intestinal pathogenic organisms that include various Salmonella strains. Dr. Mehran Ghazvini, Chairman and CEO, stated: “Test results to date have shown that Salmogenics produces healthier chickens that have increased body weight and may reduce the use of antibiotics and other antimicrobials that have been proven to be detrimental to human consumption. The vaccine to prevent Marek’s disease revolutionized the economics of the poultry industry. Because of the multiple advantages of Salmogenics, we are confident that this vaccine could also have similar economic benefits to the industry.” Salmogenics is in the final stage of testing and trials before the final U.S. Department of Agriculture/Food Safety and Inspection Service (“USDA”) approval for its commercial application. Global Green, Inc. is a green pharmaceutical company committed to identifying technology platforms and commercializing products that contain natural organisms that are not genetically modified, utilizing pharmaceutical standards. Salmogenics, the Company’s flagship product, was developed by Nutritional Health Institute Laboratories, LLC, research affiliate and majority shareholder. For more information, visit www.globalgreeninc.org. Forward-Looking Statement This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that such forward-looking statements involve risks and uncertainties, which include among others, the inherent uncertainties associated with smaller reporting companies, including without limitation, other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.